Promo Copy Sample

PHENTARA™ (fictional)

Help more of your patients with PKU reach their blood Phe targets

1In a 24-week trial, adults taking Phentara had a mean blood Phe reduction of 42% from baseline vs 4% with placebo.¹

258%
of patients on Phentara reached blood Phe ≤360 µmol/L at Week 24, vs 11% on placebo.¹

3The most common adverse reactions (≥5%) were headache, nausea, and abdominal pain.¹

Important Safety Information (fictional)
Phentara may cause headache, nausea, and abdominal pain. Monitor blood Phe regularly; continue dietary management as directed. Please see full Prescribing Information.

Reference: 1. Phentara [prescribing information, fictional]. Sections 6.1 and 14.1.

Reference annotations

1Primary endpoint

Ref 1, Section 14.1, Table 5. Both arms reported, so the comparison has context. Week 24 timepoint matches the trial.

2Responder rate

Ref 1, Section 14.1, Table 6 (secondary endpoint). Placebo rate shown alongside; threshold of 360 µmol/L stated exactly as in the source.

3Safety

Ref 1, Section 6.1, Table 2. Wording mirrors the label; fair balance carried in the ISI below the claims.

Reviewer flag I would raise

"Help more of your patients" implies a comparison with other treatments. Without head-to-head data, revise to "Help your patients reach their blood Phe targets."

Fictional product, trial, and data, created as a writing sample. No real medicine is described or promoted.

Annotated HCP promotional copy